Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Dengue virus serotype 2 envelope protein (E protein) is the major surface glycoprotein on the mature virion, composed of 180 copies arranged as homodimers. It consists of three β-sheet domains (DI central, DII dimerization with fusion loop, DIII), a membrane-proximal stem, amphipathic helix, and transmembrane anchor. At neutral pH, it forms stable prefusion dimers; low pH in endosomes triggers rearrangement to postfusion trimers, driving viral-endosomal membrane fusion for genome release. It contains a hydrophobic ligand-binding pocket at the DI/DII interface that opens via β-hairpin shift, influencing fusion pH threshold. The protein exhibits temperature-dependent morphology (smooth at 29°C, bumpy at 37°C due to loosened dimer interactions) and is targeted by neutralizing antibodies at inter-dimer, intra-dimer, and domain-specific epitopes.
Neutralization by binding quaternary epitopes across E dimers to prevent conformational reorganization and membrane fusion, Binding domain III or fusion loop to disrupt virion architecture and induce premature fusion loop exposure
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue virus serotype 2 envelope protein (DENV-2 E protein).